EUVIMEDEUVIMED entdecken
Crossref

Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity

Churu Mao, Jiebin Fang iD, Shijie Zou, Yun Huang, Xiaoming Chen, Xia Ding, Zhangyun Fang, Ningjing Zhang, Yijie Lou, Zhe Chen, Wanjing Ding, Zhongjun Ma iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c02183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Churu Mao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Antineoplastic Agents, Triple Negative Breast Neoplasms, rho-Associated Kinases. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) represents a highly aggressive and heterogeneous malignancy. Currently, multitarget drug approaches present a promising therapeutic approach for TNBC. Utilizing a combinatorial chemistry strategy to construct a virtual screening database, dual ROCK/HDAC-targeting benzothiophene compounds were identified. Notably, compound 10h effectively inhibits ROCK1/2 and HDAC1/2/3/6/8 while demonstrating potent antiproliferative activity against breast cancer cells. In an orthotopic mouse model of breast cancer, 10h significantly suppressed tumor growth without apparent toxicity. Importantly, 10h induced immunogenic cell death (ICD), promoted dendritic cells (DCs) maturation, and activated T cells, thereby initiating antitumor immunity. In conclusion, compound 10h is a novel dual-target ROCK/HDAC inhibitor that represents a promising treatment strategy for TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsAntineoplastic AgentsTriple Negative Breast Neoplasmsrho-Associated KinasesAnimalsHumansMiceFemaleCell Line, TumorCell ProliferationProtein Kinase InhibitorsHistone DeacetylasesStructure-Activity RelationshipDrug DiscoveryDrug Screening Assays, Antitumor

Substanzen

Histone Deacetylase InhibitorsAntineoplastic Agentsrho-Associated KinasesProtein Kinase InhibitorsHistone Deacetylases

Autor:innen und Institutionen

  • Institute of Marine Biology and Pharmacology, Ocean College, Zhejiang University, Zhoushan 316021, China.
  • Hainan Institute of Zhejiang University, Sanya 572025, China.
  • Key Laboratory of Digestive Pathophysiology of Zhejiang Province, The First Affiliated Hospital of Zhejiang Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.

ORCID-Profile: Jiebin Fang, Zhongjun Ma

Förderung

  • National Natural Science Foundation of China
  • Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City

Zitieren

APA

Mao, C., Fang, J., Zou, S., Huang, Y., Chen, X., Ding, X., Fang, Z., Zhang, N., Lou, Y., Chen, Z., Ding, W., & Ma, Z. (2024). Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02183

Vancouver

Mao C, Fang J, Zou S, Huang Y, Chen X, Ding X, et al. Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c02183

BibTeX
@article{Mao2024,
  author = {Mao, Churu and Fang, Jiebin and Zou, Shijie and Huang, Yun and Chen, Xiaoming and Ding, Xia and Fang, Zhangyun and Zhang, Ningjing and Lou, Yijie and Chen, Zhe and Ding, Wanjing and Ma, Zhongjun},
  title = {Discovery of the First-in-Class Dual-Target ROCK/HDAC Inhibitor with Potent Antitumor Efficacy in Vivo That Trigger Antitumor Immunity},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c02183}
}
Kostenlos starten →